

16. Van Dyck CH, Swanson CJ, et al. Lecanemab in Early Alzheimer's Disease. *New Engl J Med.* 2023; 388:9-2. DOI: 10.1056/NEJMoa2212948.
17. Swanson CJ, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody. *Alzheimer's Research & Therapy* (2021) 13:80.
18. Alzheimer's Association 2022 Alzheimer's Disease Facts and Figures. *Alzheimers Dement* 2022; 18.

Policy History		
#	Date	Change Description
1.1	Effective Date: 02/02/2023	New policy - this criteria replaces previously approved preliminary criteria.
1.0	Effective Date: 01/23/2023	Preliminary drug review

* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.